Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
117.73
-0.91 (-0.77%)
Oct 8, 2025, 9:53 AM EDT - Market open
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 19 analysts that cover Axsome Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $174.26, which forecasts a 48.02% increase in the stock price over the next year. The lowest target is $143 and the highest is $216.
Price Target: $174.26 (+48.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 8 | 9 | 10 | 10 | 11 | 11 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 17 | 17 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $179 | Strong Buy | Initiates | $179 | +52.04% | Oct 1, 2025 |
| Wells Fargo | Wells Fargo | Buy Initiates $163 | Buy | Initiates | $163 | +38.45% | Sep 3, 2025 |
| UBS | UBS | Strong Buy Maintains $133 → $144 | Strong Buy | Maintains | $133 → $144 | +22.31% | Aug 6, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $173 → $176 | Strong Buy | Maintains | $173 → $176 | +49.49% | Aug 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $184 → $189 | Buy | Maintains | $184 → $189 | +60.54% | Aug 5, 2025 |
Financial Forecast
Revenue This Year
631.08M
from 385.69M
Increased by 63.62%
Revenue Next Year
982.73M
from 631.08M
Increased by 55.72%
EPS This Year
-3.75
from -5.99
EPS Next Year
0.81
from -3.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 682.5M | 1.1B | |||
| Avg | 631.1M | 982.7M | |||
| Low | 545.9M | 762.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 77.0% | 81.3% | |||
| Avg | 63.6% | 55.7% | |||
| Low | 41.5% | 20.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.94 | 4.20 | |||
| Avg | -3.75 | 0.81 | |||
| Low | -4.87 | -2.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.